Intellia Therapeutics, Inc. — Investor Relations & Filings

Intellia Therapeutics, Inc. is a clinical-stage genome editing company focused on developing potentially curative therapeutics for severe diseases using CRISPR/Cas9 technology. The company's strategy employs a full-spectrum approach, advancing both *in vivo* programs, where genetic editing occurs directly inside the body, and *ex vivo* programs, where cells are engineered outside the body and then administered to the patient. Its clinical pipeline targets a range of genetic disorders, with a key focus on conditions such as transthyretin (ATTR) amyloidosis. Intellia aims to create a new class of medicines by developing single-course treatments with the potential to permanently correct the underlying cause of a disease.